Rivermark News

April 24, 2025

RIVERMARK MEDICAL ANNOUNCES FIRST PATIENT ENROLLED IN RAPID III CLINICAL STUDY EVALUATING THE FLOSTENT™ SYSTEM

Milwaukee, WI – [Date], 2025 – Rivermark Medical, a urology-focused medical device company committed to redefining benign prostatic hyperplasia (BPH) treatment through simple, innovative solutions, today announced the enrollment of the first patient in its RAPID III clinical study. RAPID III is a prospective, multicenter, randomized pivotal clinical trial (NCT06849258) designed to evaluate the safety and effectiveness of the FloStent™ System in men experiencing lower urinary tract symptoms caused by BPH.

October 10, 2024

Rivermark Medical Closes $30 Million Series C Financing to Advance Development of FLOSTENT™ System for Benign Prostatic Hyperplasia

Novel technology aims to provide immediate relief for patients while seamlessly integrating into routine urological visits

January 8, 2024

Rivermark Medical Announces Completion of Expanded Indication Study for the Flostent System

Rivermark Medical, announced today the successful completion of its RAPID-UR study, an extended indication study that evaluated the use of the Company’s FloStent System in patients suffering urinary retention due to BPH. The pilot study included 11 patients, and procedures were performed by Drs. Ingrid Perscky and Ruben Urena at the Pacifica Salud Costa del Este Hospital in Panama City, Panama.

January 10, 2023

Rivermark Medical announces successful first-in-human use of its Flostent System For Symptomatic BPH

Rivermark Medical, announced today the successful first-in-human (FIH) use of its FloStentTM System as part of the Company's RAPID-1 FIH clinical study. The procedures were performed on 15 patients by Principal Investigator (PI) Dr. Ingrid Perscky Arravanti and proctored by Primary Clinical Advisor Dr. Dean Elterman at the Pacifica Salud Hospital and the Panama Clinic in Panama City, Panama. The study evaluates the delivery, safety, and clinical effectiveness of the FloStent System.

December 7, 2023

Rivermark Medical Announces Fully Enrolled Multi-center OUS Clinical Trial for Innovative Benign Prostatic Hyperplasia Device

Rivermark Medical, announced today the full enrollment of its RAPID-II clinical trial, a multi-center OUS clinical trial with sites in Australia, New Zealand, and Mexico. The trial is funded by the company’s oversubscribed Series B financing which closed earlier this year and was led by Anduril Investors LLC, a physician-founded investor group, with participation from existing investors View Ventures and Cadence Healthcare Ventures.